January list of reimbursed drugs is here

In the first list effective in 2024, public funding was provided for 19 new
molecule-indications, including:

• 8 molecule - oncology indications,
• 11 molecule - non-oncology indications,
• 10 molecule indications dedicated to rare diseases.

The reimbursement notice effective January 1, 2024 (No. 73), compared to Notice 72, contains the following changes:

1. A total of 55 products or new indications were added to the list due to positive reimbursement decisions.
2. Net sales price reductions were introduced for 72 products (from PLN 0.03 to PLN 2925.32).
3. Net selling prices were increased for 49 products (from PLN 0.05 to PLN 49.00).
4. For 375 items in the notice, the patient surcharge will fall (from PLN 0.01 to PLN 51.71).
5. For 356 items in the announcement, the patient surcharge will increase (from PLN 0.01 to PLN 456.63).
6. Retail prices will be reduced for 268 products (from PLN 0.01 to PLN 51.71).
7. For 413 products, retail prices will increase (from PLN 0.01 to PLN 20.46).
8. Due to the receipt of applications to shorten the term of reimbursement decisions, or the expiration of the term of reimbursement decisions or refusal of reimbursement for the next period, the announcement will not include 72 products or indications listed in the previous announcement.

Information on setting limits on A1, A2 and A3 lists

Due to the enactment of the Law on Amendments to the Law on Reimbursement (the so-called DNUR), the pharmacy algorithm, i.e. the various stages of determining wholesale and retail prices and funding limits, has been significantly simplified:

1. sorting the list by CZN/DDD (Article 15(4) ),
2. The introduction of a wholesale price (CH, Article 2.5 ) designated as CZN + margin (Article 7.1 ),
3. The introduction of a gross wholesale price (CHB, Article 2(5a)), designated as CH+VAT,
4. The introduction of new pharmacy margins (Article 7(4 ).

All of the above changes have already been implemented on the notice effective November 1, 2023. Along with the incoming comments, a decision was made to further simplify the algorithm, i.e. to change the method of determining the so-called limit base used to determine the retail margin. From January 1, 2024, the value of x[1] will be calculated as: and rounded to 6 decimal places.

The introduction of the modification in question will result in a penny change in retail prices and patient fees.

Source: MZ